NS101
Phase 2Biologic
NS101 is one of 60 biologic programs targeting Frontotemporal Dementia. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Rogaine
PfizerPhase 3
Soliris
AstraZenecaPhase 3
Paraplatin
AAvyxa
Phase 3
Insulin 320
Novo NordiskPhase 3
Sepofarsen
PProQR Therapeutics
Phase 3
Veracept
SSebela Women's Health Inc.
Phase 3
Levocept
SSebela Women's Health Inc.
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Frontotemporal Dementia1 trial
Intravenous1 trial
Seneorineural Deafness1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NS101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- NNeuracle Science Co., LTD.